Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.
about
Accuracy of circulating placental growth factor, vascular endothelial growth factor, soluble fms-like tyrosine kinase 1 and soluble endoglin in the prediction of pre-eclampsia: a systematic review and meta-analysisThe complement system and adverse pregnancy outcomesLow-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary eliminationAssociation between abnormal uterine artery Doppler flow velocimetry, risk of preeclampsia, and indices of arterial structure and function: a pilot study.Relation between maternal angiogenic factors and utero-placental resistance in normal first- and second-trimester pregnancies.The change in concentrations of angiogenic and anti-angiogenic factors in maternal plasma between the first and second trimesters in risk assessment for the subsequent development of preeclampsia and small-for-gestational age.Circulating levels of copeptin, a novel biomarker in pre-eclampsia.Defining normal and abnormal fetal growth: promises and challenges.Is fetal growth restriction associated with a more severe maternal phenotype in the setting of early onset pre-eclampsia? A retrospective studyFirst-trimester placental ultrasound and maternal serum markers as predictors of small-for-gestational-age infants.Plasma soluble endoglin concentration in pre-eclampsia is associated with an increased impedance to flow in the maternal and fetal circulations.Retinol binding protein 4--a novel association with early-onset preeclampsia.The vascular endothelial growth factor family in adverse pregnancy outcomes.Cell free expression of hif1α and p21 in maternal peripheral blood as a marker for preeclampsia and fetal growth restrictionShould bilateral uterine artery notching be used in the risk assessment for preeclampsia, small-for-gestational-age, and gestational hypertension?Placental growth factor for the prediction of adverse outcomes in patients with suspected preeclampsia or intrauterine growth restriction.An imbalance between angiogenic and anti-angiogenic factors precedes fetal death in a subset of patients: results of a longitudinal study.Protein profiling of preeclampsia placental tissuesCirculating angiogenic and antiangiogenic factors in women with eclampsia.Doppler ultrasound evaluation in preeclampsiaPre-eclampsia: pathophysiology, diagnosis, and managementMaternal serum adiponectin multimers in preeclampsia.Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practicePlacental lesions associated with maternal underperfusion are more frequent in early-onset than in late-onset preeclampsiaFetal growth restriction: current perspectivesPregnancy in patients with chronic kidney disease: Maternal and fetal outcomes.Microbial invasion of the amniotic cavity in preeclampsia as assessed by cultivation and sequence-based methodsPlGF in a clinical setting of pregnancies at risk of preeclampsia and/or intrauterine growth restriction.The "Great Obstetrical Syndromes" are associated with disorders of deep placentationLate-onset preeclampsia is associated with an imbalance of angiogenic and anti-angiogenic factors in patients with and without placental lesions consistent with maternal underperfusion.Serum and plasma determination of angiogenic and anti-angiogenic factors yield different results: the need for standardization in clinical practice.A prospective cohort study of the value of maternal plasma concentrations of angiogenic and anti-angiogenic factors in early pregnancy and midtrimester in the identification of patients destined to develop preeclampsiaA decrease in maternal plasma concentrations of sVEGFR-2 precedes the clinical diagnosis of preeclampsiaTiming of ischemic insult alters fetal growth trajectory, maternal angiogenic balance, and markers of renal oxidative stress in the pregnant rat.Preeclampsia and pregnancies with small-for-gestational age neonates have different profiles of complement split products.Placental growth hormone is increased in the maternal and fetal serum of patients with preeclampsiaMaternal serum soluble CD30 is increased in normal pregnancy, but decreased in preeclampsia and small for gestational age pregnanciesDetection and confirmation of serum lipid biomarkers for preeclampsia using direct infusion mass spectrometry.Prediction of pre-eclampsia by a combination of maternal history, uterine artery Doppler, and mean arterial pressure (a prospective study of 200 cases).Twin-to-twin transfusion syndrome: an antiangiogenic state?
P2860
Q26825271-F1A537D7-4411-40BC-A497-4DEA39F85B88Q26863600-695D6651-576E-42E3-AA1A-334B40A2D706Q28538906-C3B0469A-E039-47CC-8F51-5A77D1006E77Q33337837-5A181546-57B6-42C1-BC19-BA48CAA05993Q33667332-CC035888-BCC6-4925-8DCD-12463F356C26Q33755648-28B08463-770C-4B1A-BA4B-8555B74BC385Q33875627-C178063E-ADF7-4879-92C2-8F8138A34632Q33886558-DF1AABED-9C70-4E04-A850-0B7FA7D26DFFQ34064856-D526710E-6AAD-4B25-8337-D6E58C8A1F33Q34111720-F47E6059-31F4-4C85-ADC3-C58AB3D28217Q34151967-69950913-DBA7-406F-9DD1-3D125AF432DFQ34234671-AAEE14D3-F62F-451D-9E5D-F40ECD0AFB51Q34267491-F449463F-0E37-4D75-90AF-AB0CA943CC9BQ34277918-CC447069-3DD9-4758-AB9B-30B05EAF7C3AQ34488052-7C531CA3-57FD-44A0-8D67-BC9F6A726DAEQ34500006-53771520-F3A2-41F9-8F1E-DBA723517A9FQ34505090-E4CC5A0F-8981-430A-A38E-501CEA39B01CQ34506462-20D14124-B7DC-4881-9A16-74DC48B269BBQ34670638-806B94F7-8239-4440-8A5B-6D17AE79BFD0Q35046946-1FC77F6B-62E7-4273-87DA-38A6B592666EQ35141777-23416DFA-A728-4E76-A3A1-A7DD6951D343Q35194054-832155B5-4F9D-431B-BCEE-D94435EAA5ECQ35204444-03B50BDA-46A6-4AA9-91A1-499DA60E5C27Q35542826-7E693DC9-1919-4CA8-9D25-AA6D46F0A571Q35756030-A0A10EAE-0A18-438C-BBCE-3C49439BE12AQ35830262-950023D9-AD0B-4C98-A313-DA4990A34960Q35886564-0F33C266-FDCE-4EE4-BD91-7605ABAE9EEFQ35974116-2736F015-FF14-499C-A5E5-E84C3223A582Q36015615-66D9ECE7-8D9A-46BD-A083-5B5797B55545Q36107337-02D9EA81-E76C-4607-8F06-11CBA08ACE15Q36185056-7EBEEFD5-2E3A-4103-B909-A961396216B8Q36189562-25128BD5-AC0B-4880-B6A9-C2B92B3653AEQ36221448-41DD02FB-129F-4AD6-987C-6D16203685CAQ36309225-AC99CDBA-A9D5-4CE7-A32B-A1908C169206Q36351625-37453768-DB2C-4F5C-8E7D-8BBB6C1CC967Q36512059-5630A799-5AF0-414C-A10E-79BCCC0B15FAQ36512063-03E3AE37-0462-4A49-AF06-1084E79DA53EQ36731791-F27B75A1-8FEF-477D-AF77-0DA1925B9299Q36831976-2B08EDEA-EF5B-4931-BC19-2AECB869B33EQ37183878-890F8EA1-261C-4C0D-9890-F33C8E55BDA3
P2860
Identification of patients at risk for early onset and/or severe preeclampsia with the use of uterine artery Doppler velocimetry and placental growth factor.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Identification of patients at ...... y and placental growth factor.
@ast
Identification of patients at ...... y and placental growth factor.
@en
type
label
Identification of patients at ...... y and placental growth factor.
@ast
Identification of patients at ...... y and placental growth factor.
@en
prefLabel
Identification of patients at ...... y and placental growth factor.
@ast
Identification of patients at ...... y and placental growth factor.
@en
P2093
P2860
P921
P1476
Identification of patients at ...... y and placental growth factor.
@en
P2093
Jimmy Espinoza
Juan Pedro Kusanovic
Jyh Kae Nien
Luis F Gonçalves
Luis Medina
Mario Carstens
Roberto Romero
Rogelio Gonzalez
Sonia Hassan
P2860
P304
P356
10.1016/J.AJOG.2006.11.002
P407
P577
2007-04-01T00:00:00Z